RT Journal Article
SR Electronic
T1 Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.03.23287902
DO 10.1101/2023.04.03.23287902
A1 Michael, Benedict D.
A1 Dunai, Cordelia
A1 Needham, Edward J.
A1 Tharmaratnam, Kukatharmini
A1 Williams, Robyn
A1 Huang, Yun
A1 Boardman, Sarah A.
A1 Clark, Jordan
A1 Sharma, Parul
A1 Subramaniam, Krishanthi
A1 Wood, Greta K.
A1 Collie, Ceryce
A1 Digby, Richard
A1 Ren, Alexander
A1 Norton, Emma
A1 Leibowitz, Maya
A1 Ebrahimi, Soraya
A1 Fower, Andrew
A1 Fox, Hannah
A1 Tato, Esteban
A1 Ellul, Mark
A1 Sunderland, Geraint
A1 Held, Marie
A1 Hetherington, Claire
A1 Nkongho, Franklyn
A1 Palmos, Alish
A1 Grundmann, Alexander
A1 Stewart, James P.
A1 Griffiths, Michael
A1 Solomon, Tom
A1 Breen, Gerome
A1 Coles, Alasdair
A1 Cavanagh, Jonathan
A1 Irani, Sarosh R.
A1 Vincent, Angela
A1 Taams, Leonie
A1 Menon, David K.
YR 2023
UL http://medrxiv.org/content/early/2023/04/04/2023.04.03.23287902.abstract
AB We measured brain injury markers, inflammatory mediators, and autoantibodies in 203 participants with COVID-19; 111 provided acute sera (1-11 days post admission) and 56 with COVID-19-associated neurological diagnoses provided subacute/convalescent sera (6-76 weeks post-admission). Compared to 60 controls, brain injury biomarkers (Tau, GFAP, NfL, UCH-L1) were increased in acute sera, significantly more so for NfL and UCH-L1, in patients with altered consciousness. Tau and NfL remained elevated in convalescent sera, particularly following cerebrovascular and neuroinflammatory disorders. Acutely, inflammatory mediators (including IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) were higher in participants with altered consciousness, and correlated with brain injury biomarker levels. Inflammatory mediators were lower than acute levels in convalescent sera, but levels of CCL2, CCL7, IL-1RA, IL-2Rα, M-CSF, SCF, IL-16 and IL-18 in individual participants correlated with Tau levels even at this late time point. When compared to acute COVID-19 patients with a normal GCS, network analysis showed significantly altered immune responses in patients with acute alteration of consciousness, and in convalescent patients who had suffered an acute neurological complication. The frequency and range of autoantibodies did not associate with neurological disorders. However, autoantibodies against specific antigens were more frequent in patients with altered consciousness in the acute phase (including MYL7, UCH-L1, GRIN3B, and DDR2), and in patients with neurological complications in the convalescent phase (including MYL7, GNRHR, and HLA antigens). In a novel low-inoculum mouse model of SARS-CoV-2, while viral replication was only consistently seen in mouse lungs, inflammatory responses were seen in both brain and lungs, with significant increases in CCL4, IFNγ, IL-17A, and microglial reactivity in the brain. Neurological injury is common in the acute phase and persists late after COVID-19, and may be driven by a para-infectious process involving a dysregulated host response.(a) The acute cohort (days 1-11 post-hospitilisation) showed elevated pro-inflammatory cytokines, brain injury markers, and autoantibodies. The sub-acute/convalescent cohort (weeks to months post-COVID+ve test) retained elevated brain injury markers but lower proinflammatory cytokines and autoantibodies.(b) The mouse model of para-infectious brain with no active viral replication, had increased cytokines (IFNγ and IL-17A) and microglia reactivity (increased Iba1 expression).Created using Biorender.Competing Interest StatementTS is Director of The Pandemic Institute which has received funding from Innova and CSL Seqirus and Aviva and DAM Health. TS was an advisor to the GSK Ebola Vaccine programme and the Siemens Diagnostic Programme. TS Chaired the Siemens Healthineers Clinical Advisory Board. TS Co-Chaired the WHO Neuro-COVID task force and sat on the UK Government Advisory Committee on Dangerous Pathogens, and the Medicines and Healthcare Products Regulatory Agency (MHRA) Expert Working Group on Covid-19 vaccines. TS Advised to the UK COVID-19 Therapeutics Advisory Panel (UK-TAP). TS was a Member of COVID-19 Vaccines Benefit Risk Expert Working Group for the Commission on Human Medicines (CHM) committee of the Medicines and Healthcare products Regulatory Agency (MHRA). TS has been a member of the Encephalitis Society since 1998 and President of the Encephalitis Society since 2019. Funding StatementBDM is supported by the UKRI/MRC (MR/V03605X/1), the MRC/UKRI (MR/V007181/1), MRC (MR/T028750/1) and Wellcome (ISSF201902/3). CD is supported by MRC (MC_PC_19044). We would like to acknowledge the Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (Grant Reference: C18616/A25153). We acknowledge the Liverpool Centre for Cell Imaging (CCI) for provision of imaging equipment (Dragonfly confocal microscope) and excellent technical assistance (BBSRC grant number BB/R01390X/1). DKM and EN are supported by the NIHR Cambridge Biomedical Centre and by NIHR funding to the NIHR BioResource (RG94028 and RG85445), and by funding from Brain Research UK (201819-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the East of England Cambridge Central Research NIHR BioResource REC ref. 17/EE/0025 gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://github.com/Marien-kaefer/ramification_index